DFsn collaborates with Highwire to down-regulate the Wallenda/DLK kinase and restrain synaptic terminal growth by Wu, Chunlai et al.
15 August 2007
DFsn collaborates with Highwire to down-regulate
the Wallenda/DLK kinase and restrain synaptic terminal growth
Chuniai Wu et al.
Neural Development 2007, 2:16
http://www.neuraldevelopment.com/content/2/1/16
www.neuraldevelopment.com
NEURAL DEVELOPMENTBioMed  Central
Page 1 of 14
(page number not for citation purposes)
Neural Development
Open Access Research article
DFsn collaborates with Highwire to down-regulate the 
Wallenda/DLK kinase and restrain synaptic terminal growth
Chunlai Wu, Richard W Daniels and Aaron DiAntonio*
Address: Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, MO 63110, USA
Email: Chunlai Wu - cwu@wustl.edu; Richard W Daniels - rdaniels@wustl.edu; Aaron DiAntonio* - diantonio@wustl.edu
* Corresponding author    
Abstract
Background:  The growth of new synapses shapes the initial formation and subsequent
rearrangement of neural circuitry. Genetic studies have demonstrated that the ubiquitin ligase
Highwire restrains synaptic terminal growth by down-regulating the MAP kinase kinase kinase
Wallenda/dual leucine zipper kinase (DLK). To investigate the mechanism of Highwire action, we
have identified DFsn as a binding partner of Highwire and characterized the roles of DFsn in
synapse development, synaptic transmission, and the regulation of Wallenda/DLK kinase
abundance.
Results: We identified DFsn as an F-box protein that binds to the RING-domain ubiquitin ligase
Highwire and that can localize to the Drosophila neuromuscular junction. Loss-of-function mutants
for DFsn have a phenotype that is very similar to highwire mutants – there is a dramatic overgrowth
of synaptic termini, with a large increase in the number of synaptic boutons and branches. In
addition, synaptic transmission is impaired in DFsn mutants. Genetic interactions between DFsn and
highwire mutants indicate that DFsn and Highwire collaborate to restrain synaptic terminal growth.
Finally, DFsn regulates the levels of the Wallenda/DLK kinase, and wallenda is necessary for DFsn-
dependent synaptic terminal overgrowth.
Conclusion: The F-box protein DFsn binds the ubiquitin ligase Highwire and is required to down-
regulate the levels of the Wallenda/DLK kinase and restrain synaptic terminal growth. We propose
that DFsn and Highwire participate in an evolutionarily conserved ubiquitin ligase complex whose
substrates regulate the structure and function of synapses.
Background
The connectivity and functionality of a neural circuit
depends on the structure of its constituent neurons' pres-
ynaptic fields. Different neurons make very different syn-
aptic trees – a serotonergic neuron will synapse with
thousands of neurons throughout the brain, while climb-
ing fibers from the medulla may synapse with only a sin-
gle Purkinje cell in the cerebellum. Individual neurons
with the same identity can also have different sized synap-
tic arbors and this has functional consequences: during
synaptic competition at the vertebrate neuromuscular
junction (NMJ), motoneurons with larger arbors are at a
disadvantage when competing against those with smaller
arbors [1]. Molecular mechanisms that control the size
and structure of a neuron's presynaptic field are key regu-
lators of the development, function, and plasticity of neu-
ral circuits.
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In Drosophila, genetic studies have identified a number of
signaling pathways that regulate the morphology of the
presynaptic arbor made by motoneurons onto muscles
(reviewed in [2]). One such pathway requires highwire – in
highwire mutants there is a dramatic increase in the com-
plexity of the synaptic terminal, with a large increase in
the number of synaptic boutons and branches [3]. This
function for highwire is evolutionarily conserved: studies
in worms, fish, and mammals all suggest that highwire
homologs are required for normal synaptic development.
In Caenorhabditis elegans, the homolog rpm-1 regulates the
number, spacing, and morphology of presynaptic active
zones [4,5], mutations in the zebrafish homolog esrom
disrupt retinotectal projections [6], while mice carrying
large deletions that remove the murine homolog phr1 and
adjacent genes disrupt NMJ morphology [7].
Highwire and its homologs are huge proteins on the order
of 5,000 amino acids that share a series of domains that
likely perform distinct functions. These include an amino-
terminal Ran GTPase exchange factor domain that can
inhibit adenylate cyclase [8], two Phr repeats of unknown
function, a Myc-binding domain [9], and a carboxy-termi-
nal RING domain that can function as an E3 ubiquitin
ligase. Numerous studies demonstrate a central role for
this ubiquitin ligase activity in the molecular mechanism
of Highwire action. In both C. elegans and zebrafish, the
isolated RING domain can promote ubiquitination in
vitro [6,10], and mutations that disrupt the RING finger
abolish function [6,11]. In addition, overexpression of
ubiquitin hydrolases enhances the highwire  phenotype
and promotes synaptic terminal overgrowth at the Dro-
sophila NMJ [12].
What are the key targets of Highwire regulation? As befits
a large, multi-domain protein, Highwire and its homologs
interact with many candidate targets, including the co-
SMAD Medea, adenylate cyclases, members of the tuber-
ous sclerosis (TSC) complex, and the oncogenic protein
Myc [8,9,13,14]. One particularly compelling candidate is
the mitogen-activated protein (MAP) kinase kinase kinase
(MAPKKK) Wallenda in Drosophila  and its C. elegans
homologue dual leucine zipper kinase (DLK) [10,15]. In
both worms and flies, levels of the Wallenda/DLK kinase
are increased in the absence of highwire/rpm-1, the synap-
tic defects of highwire/rpm-1 mutants are suppressed by
mutations in either Wallenda/DLK or their downstream
MAP kinases, and increasing the levels of Wallenda/DLK
is sufficient to phenocopy the synaptic defects of highwire/
rpm-1 mutants. In C. elegans, DLK is required for some but
not all rpm-1 phenotypes, indicating that rpm-1 may have
other targets. In Drosophila, wallenda is necessary for all of
the synaptic morphology defects in a highwire mutant, but
it is not required for highwire-dependent regulation of syn-
aptic function [15]. Since the regulation of synaptic trans-
mission by highwire requires a functional ubiquitin ligase
domain [11], Highwire very likely targets at least one pro-
tein in addition to Wallenda.
RING finger E3 ubiquitin ligases can function to promote
ubiquitination of target proteins on their own or as mem-
bers of large E3 protein complexes [16]. In C. elegans,
RPM-1 binds to Cullin-1, Skp-1, and the F-box protein
FSN-1, leading to the hypothesis that RPM-1 functions as
part of an atypical SCF (Skp1-cullin-F box protein) E3
ubiquitin ligase complex [17]. F-box proteins such as FSN-
1 determine the substrate specificity of the E3 ligase com-
plex [18]. Mutations in C. elegans fsn-1 lead to many of the
same phenotypes as rpm-1 mutants, consistent with the
hypothesis that they function together to regulate synapse
development. However, genetic and biochemical data
indicate that the receptor tyrosine kinase anaplastic lym-
phoma kinase (ALK) is the functionally relevant target of
FSN-1, since levels of ALK increase in an fsn-1 mutant and
the fsn-1 phenotype is suppressed by mutations in ALK
[17]. However, rpm-1 mutants are suppressed much more
strongly by DLK than by ALK [10], so rpm-1 and fsn-1 may
target different substrates. In fact, it is not known if FSN-1
biochemically or genetically interacts with DLK. This
presents a paradox – two components of the same E3
ligase work together to regulate synaptic development,
but apparently via different molecular pathways.
These findings in C. elegans raise a number of questions.
First, is the binding between FSN-1 and RPM-1/Highwire
conserved in Drosophila? Since the C. elegans genome
encodes more than 300 F-box proteins and Drosophila
encodes only 33, this is not a given [18,19]. Second, does
Fsn regulate synaptic terminal growth and synaptic func-
tion in Drosophila? Third, does Fsn collaborate with High-
wire to regulate the levels of the Wallenda/DLK kinase and
is this necessary for normal synaptic development?
Fourth, does the regulation of other Highwire targets
require collaboration with Fsn, or does Highwire function
alone or with other F-box proteins? We identified the Dro-
sophila homolog of FSN-1, DFsn, in a proteomic screen as
a Highwire-binding protein. We have addressed the ques-
tions above by undertaking a genetic analysis of DFsn
function in Drosophila. Our results demonstrate that DFsn
collaborates with Highwire to restrain synaptic terminal
growth by down-regulating the same target, the Wallenda/
DLK kinase.
Results
Drosophila Fsn is a Highwire-interacting protein
In an effort to understand the mechanism of action of
Highwire, we have identified Highwire-binding proteins
from the Drosophila nervous system. Tandem affinity puri-
fication (TAP) is a powerful two-step purification scheme
for isolating a protein of interest and its binding partnersNeural Development 2007, 2:16 http://www.neuraldevelopment.com/content/2/1/16
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[20]. We generated transgenic flies expressing a TAP-
tagged Highwire and demonstrated that this fusion pro-
tein is functional since it rescues the highwire loss-of-func-
tion phenotypes [11]. We also generated a transgene
encoding TAP-tagged HighwireΔRING (HiwΔRING),
which carries two Cys-to-Ser mutations in the conserved
RING domain, and demonstrated that HiwΔRING acts as
a potent dominant negative when expressed in neurons
[11]. Both highwire transgenes were tested in our TAP sys-
tem. We found that HiwΔRING shows a much stronger
enrichment in the final complex than Highwire, possibly
because of a higher stability of HiwΔRING (data not
shown). Thus, we expressed TAP-HiwΔRING in the Dro-
sophila central nervous system (CNS), purified full-length
HiwΔRING and associated proteins (see Materials and
methods for details), and analyzed the purified complex
by two independent approaches. First, the eluted proteins
were resolved on SDS-PAGE and the sypro-stained protein
bands were excised, digested with trypsin, and subjected
to liquid chromatography-tandem mass spectrometry
(LC-MS/MS). The searching program MASCOT was used
to identify the protein species. Peptide mass fingerprint-
ing and MS/MS peptide sequencing (data not shown)
identified the bait protein Highwire as the 600 kDa band
in Figure 1a. In addition, CG4643 was identified as the 27
kDa band indicated in Figure 1a based on the recovery of
two unique peptides (SDLLASVSTYK, NVYIKPNGFTLHR)
that are present in CG4643. Second, LC-MS/MS was used
to directly analyze the purified protein complex without
an intermediate SDS-PAGE separation. Again, in addition
to Highwire peptides, five unique peptides from CG4643
were recovered (ESLKSDLLASVSTYK, NPVAQSTDAAR,
YQVGER, IRVILDCEDNTLSFEK, NYEFLGVAFR).
CG4643 is predicted to encode a 27 kDa protein contain-
ing an F-box domain, a WD-40 repeat, and a spla and
ryanodine receptor (SPRY) domain. Its closest homolog
in C. elegans is FSN-1, which is composed of the same
functional domains and which binds to the RPM-1, the C.
elegans  homolog of Highwire. The two proteins share
41.9% homology, and define a small sub-family of F-box
proteins with SPRY domains of which there is only a sin-
gle member in worms, flies, mice (F-box protein 45 (Gen-
Bank:AAH26799)), and humans (hCG1734196
(GenBank:EAW53643)) with high homology across spe-
cies (Figure 1b). Based on the sequence similarity of
CG4643 and FSN-1, we have renamed CG4643 DFsn, for
Drosophila Fsn.
The fact that TAP-HiwΔRING can pull down DFsn indi-
cates that an intact RING domain is not required for the
Highwire-DFsn interaction. To test whether wild-type
Highwire also interacts with DFsn, we performed the fol-
lowing co-immunoprecipitation experiments. Since we
have been unable to generate an antibody that recognizes
endogenous DFsn, we generated transgenic flies that
express His-Myc-tagged DFsn. As described below, the
transgene encoding this is functional since it can rescue a
DFsn  mutant. We expressed His-Myc-tagged DFsn
throughout the nervous system and performed immuno-
precipitations from third instar larvae brains. Immuno-
precipitations (IPs) and western blot analysis was
performed with either affinity-purified polyclonal anti-
bodies raised against Highwire [11] or a monoclonal anti-
body to Myc. As shown in Figure 1c, Myc-DFsn is present
when endogenous Highwire is immunoprecipitated. Con-
versely, endogenous Highwire is detected in the IP frac-
tion when Myc-DFsn is immunoprecipitated by the anti-
Myc antibody. In addition, neither endogenous Highwire
nor Myc-DFsn is detected when a control protein, Dro-
sophila  vesicular Glutamate transporter (DVGLUT), is
immunoprecipitated from Myc-DFsn expressing larval
brains (data not shown). These data demonstrate that
endogenous Highwire physically interacts with DFsn.
While eukaryotic genomes can express hundreds of F-box
proteins and a similar number of RING domain ubiquitin
ligases [18,21], these data and the previous work of Liao
et al. [17] demonstrate that the physical interaction
between Highwire/RPM-1 and Fsn is evolutionarily con-
served.
Since our efforts to generate an antibody against DFsn
were unsuccessful, we generated a functional green fluo-
rescent protein (GFP)-tagged DFsn transgene. When the
transgene is expressed by a pan-neuronal Gal4 driver,
GFP-DFsn localizes to the NMJ (Figure 1e,h). Double
staining with markers for synaptic vesicles (Figure 1e–g)
and periactive zones (Figure 1h–j) demonstrates that GFP-
DFsn is not restricted to any of these compartments. GFP-
DFsn is also detectable in the axon and neuronal cell body
(data not shown), although the staining of GFP-DFsn is
much stronger in synaptic boutons than in the pretermi-
nal axon (Figure 1e, arrow), suggesting a synaptic enrich-
ment. GFP-Highwire encoded by a pan-neuronally
expressed transgene has a very similar localization pattern
[11]. These data are consistent with the presence of a
Highwire-DFsn complex at the NMJ.
DFsn is required to restrain synaptic terminal growth at the 
NMJ
C. elegans FSN-1 is required for normal presynaptic differ-
entiation [17], and its phenotype partially overlaps with
the rpm-1 phenotype. Having shown that the Highwire-
DFsn interaction is conserved in Drosophila, we wished to
test whether DFsn is also required for normal synapse
development. We obtained a chromosomal deficiency,
Df(2R)7872, that removes DFsn and flanking genes, as
well as a transposable-element-insertion mutant in the
DFsn locus from the Drosophila stock center. The insert,
P(f06595), is a piggyBac P-element inserted in the secondNeural Development 2007, 2:16 http://www.neuraldevelopment.com/content/2/1/16
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DFsn is identified as a Highwire-interacting protein Figure 1
DFsn is identified as a Highwire-interacting protein. (a) The Highwire-associated complex was purified by the TAP procedure 
(see Materials and methods) and analyzed by one-dimensional SDS-PAGE gel followed by Sypro Ruby staining. A representative 
gel is shown and full-length Highwire is marked with an arrowhead. Mass spectrometry identified one of the Highwire-interact-
ing proteins as DFsn (approximately 27 kDa, indicated by arrow). (b) Schematic of DFsn protein (CG4643 in Drosophila) and 
its homologs in C. elegans, mouse and human. Green boxes denote the F-Box and blue boxes denote the SPRY domain. The 
overall amino acid identity to the DFsn protein is reported in the parenthesis on the right. (c) Larval brain lysate of either wild 
type (WT) flies or flies neuronally expressing His-Myc-tagged DFsn (HM-DFsn) was subject to co-immunoprecipitation (IP) 
with either anti-Highwire antibody (Hiw2b) or anti-Myc antibody (9E10). Both the input and the IP complexes were analyzed 
by western blots (WB) with anti-Myc or anti-Highwire antibody. (d-j) When expressed in the central nervous system, GFP-
DFsn is localized to NMJs. The localization of GFP-DFsn at the synapses is analyzed by double staining with anti-GFP and synap-
tic vesicle marker DVGLUT (e-g), or periactive zone marker FasII (h-j). In (d), the presynaptic terminal of (e-g) was visualized 
by HRP (horseradish peroxidase) staining; the arrow indicates a preterminal axon.
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exon of the DFsn, 121 base-pairs upstream of the start
codon (Figure 2a,b). RT-PCR data demonstrate that tran-
scription of DFsn is disrupted in homozygous f06595 and
hemizygous P(f06595)/Df(2R)7872 mutants (Figure 2c).
Both the homozygous and hemizygous adult DFsn
mutants are viable and male-sterile. Morphological analy-
sis of the NMJ from P(f06595)/P(f06595) and P(f06595)/
Df(2R)7872 larvae reveals dramatic synaptic terminal
overgrowth (Figure 3). We quantified this phenotype at
the NMJ of a single identified motoneuron, MN4-1b [22],
which forms the type Ib innervation onto muscle 4, but all
phenotypes are qualitatively similar at every type I NMJ,
including the muscle 6/7 NMJ (Additional file 1). We
quantified three metrics of synaptic structure: bouton
number, number of branch points and synaptic span (the
extent of the muscle covered by the synapse). The
P(f06595)/Df(2R)7872 mutant shows an almost four-
fold increase in both bouton number and number of
branch points when compared with the wild-type NMJ
(Figure 3). The synaptic span of the P(f06595)/
Df(2R)7872 mutant is also increased from 18% in wild
type to 30% (Figure 3). This synaptic terminal overgrowth
is quantitatively and qualitatively very similar to that
observed in a highwire null mutant [11]. The homozygous
P(f06595)/P(f06595) mutant also has a large increase in
bouton number, branch point number, and synaptic
span, but the phenotype is less severe than in the
P(f06595)/Df(2R)7872 mutant. Since the mutant pheno-
type of P(f06595) is enhanced when placed over a dele-
tion, P(f06595) is behaving as a genetic hypomorph.
Highwire regulates synaptic terminal growth presynapti-
cally. If DFsn functions with Highwire to restrain this
growth, then it should also be required in the presynaptic
motoneuron. We generated transgenic flies capable of
expressing DFsn in a tissue-specific manner (UAS-GFP-
DFsn). We expressed GFP-DFsn in neurons with elav-
Gal4, a pan-neural Gal4 driver, in the DFsn mutant back-
ground [P(f06595)/Df7872; UAS-GFP-DFsn/elav Gal4].
To assess rescue, we again quantified bouton number,
synaptic branching, and synaptic span at the MN4-Ib NMJ
onto muscle 4. All of these aspects of synaptic terminal
overgrowth are rescued by the presynaptic expression of
DFsn (Figure 3). The presence of the elav-Gal4 transgene
without the UAS-GFP-DFsn transgene fails to rescue the
DFsn mutant (p > 0.4 for number of boutons and branch
points). Furthermore, synaptic terminal overgrowth of the
DFsn mutant is also fully rescued when GFP-DFsn is
expressed selectively in motoneurons (driven by D42;
Additional file 1), indicating DFsn functions cell autono-
mously in the motoneuron to restrain synaptic terminal
growth. Although we only quantified NMJs onto muscle
4, all type I NMJs, including those on muscle 6/7, show
qualitatively similar rescue (Additional file 1). The trans-
gene encoding the His-Myc-tagged DFsn also rescued the
mutant phenotype (data not shown), so the fusion pro-
teins used for immunoprecipitation and immunolocaliza-
tion above are both functional. These data demonstrate
that DFsn is responsible for the phenotype of the
P(f06595) mutant, which we have renamed DFsnf06595.
These data demonstrate that DFsn is required in the pres-
ynaptic motoneuron to restrain synaptic terminal growth
at the Drosophila NMJ.
Drosophila Fsn is required for normal synaptic function
Highwire is not only required to restrain synaptic terminal
growth, but also to promote synaptic function. Both of
these activities require the ligase function of Highwire, but
Highwire regulates distinct molecular pathways to affect
synapse morphology and function. Since F-box proteins
can confer specificity to ubiquitin ligases, we wondered
whether DFsn is also required to regulate synaptic release.
We analyzed synaptic transmission in DFsn mutants by
performing intracellular recordings from muscle 6 (seg-
ments A3 and A4) of third instar larvae and measured
both spontaneous and evoked neurotransmitter release
(Figure 4). Quantal size (mEJP amplitude), the postsynap-
tic response to the spontaneous fusion of a single synaptic
vesicle, is unchanged in DFsn mutants (Figure 4b). How-
ever, evoked release is greatly reduced – DFsn mutant lar-
vae have a 70% reduction (p < 0.001) in the excitatory
junctional potential (EJP) compared with wild type (Fig-
ure 4c). The reduction in evoked release is due to a 66%
decrease (p < 0.001) in quantal content, the number of
vesicles released by a nerve following an action potential,
in the mutant (Figure 4d). Presynaptic expression of the
wild-type UAS-DFsn transgene rescues the deficit in both
evoked neurotransmitter release and quantal content (Fig-
ure 4), indicating DFsn functions presynaptically to regu-
late synaptic function. The decrease in evoked synaptic
release observed in the DFsn mutant is very similar to that
seen in highwire null mutants, although the hypomorphic
DFsn mutant does not show the same modest decrease in
quantal size observed in the hiw null mutant [11].
DFsn genetically interacts with highwire to restrain 
synaptic terminal growth
The analysis above demonstrates that DFsn and highwire
loss-of-function mutants have very similar morphological
and physiological phenotypes. Since they physically inter-
act, these similar phenotypes suggest that DFsn and High-
wire function together in a complex. To test this
hypothesis, we analyzed genetic interactions between
DFsn  and  highwire. If DFsn and Highwire function
together in a complex, then we predict that hypomorphic
(partial loss-of-function) alleles of DFsn should enhance
the phenotype of a hypomorphic highwire  mutant. We
generated double mutants between the hypomorphic
DFsnf06595 mutant and the weak highwire allele hiwND51,
which carries an amino acid change at residue 2054Neural Development 2007, 2:16 http://www.neuraldevelopment.com/content/2/1/16
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A transposable-element-insertion mutant of DFsn Figure 2
A transposable-element-insertion mutant of DFsn. (a) The gene structure of DFsn. The black-arrowed boxes indicate exons. A 
piggyBac transposable element, P(f06595) (represented by a big triangle), inserts in the second exon, 121 base-pairs upstream 
of the start codon (indicated by the red arrow). The red arrowhead points to the stop codon. Green arrows mark forward or 
reverse primers used in the PCR experiments described in (b, c). (b) PCR reactions using the indicated primer pairs and 
genomic DNA of wild-type or DFsnf06595/Df [P(f06595)/Df(2R)7872] flies demonstrate the location of the P-element insertion. 
(c) RT-PCRs were performed using total RNAs from wild-type, DFsnf06595/Df or DFsnf06595 [P(f06595)/P(f06595)] flies and poly 
dT oligo primer for the reverse transcription reactions. PCR performed with the indicated primer pairs at 26 cycles are shown 
here. The normal transcript in the wild type (accessed by primer pairs AF and DF) is disrupted in the DFsn mutants. Additional 
cycles of PCR only revealed mis-spliced DFsn transcripts in the DFsn mutants. Transcripts of TBP (TATA box binding protein) 
and rp49 (ribosomal protein 49) are analyzed as internal control.
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DFsn is required to restrain synaptic terminal growth at the NMJ Figure 3
DFsn is required to restrain synaptic terminal growth at the NMJ. (a) Representative confocal images of muscle 4 synapses co-
stained with DVGLUT (green) and FasII (red), in wild-type (WT), and DFsnf06595/Df-Res [presynaptic rescue: P(f06595)/
Df(2R)7872; elav Gal4/UAS-GFP-DFsn] third instar larvae. (b-d) Quantification of bouton number (b), number of branch points 
(c) and synaptic span (d) in WT, DFsnf06595 [P(f06595)/P(f06595)], DFsnf06595/Df and DFsnf06595/Df-Res third instar larvae; n = 36, 
21, 23 and 29 cells, respectively. Both DFsnf06595 and DFsnf06595/Df are significantly different from WT for all parameters meas-
ured (p < 0.001), while DFsnf06595/Df shows a more severe phenotype in number of boutons and number of branching points 
than DFsnf06595 (p < 0.05). The morphological defects in DFsnf06595/Df are rescued by presynaptic expression of GFP-DFsn in all 
parameters measured (p < 0.001 for DFsnf06595/Df-Res versus DFsnf06595/Df; p > 0.5 for DFsnf06595/Df-Res versus WT).
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DFsn is required for normal synaptic function Figure 4
DFsn is required for normal synaptic function. (a) Representative traces of evoked and spontaneous transmitter release 
recorded from wild-type (WT), DFsnf06595/Df [P(f06595)/Df(2R)7872], DFsnf06595/Df-Res [presynaptic rescue: P(f06595)/
Df(2R)7872; elav Gal4/UAS-HM-DFsn] and DFsnf06595/Df; wnd1/wnd3 third instar larvae. (b-e) The mean mEJP amplitude (b), EJP 
amplitude (c) and quantal content (d) are plotted for WT, DFsnf06595/Df, DFsnf06595/Df-Res and DFsnf06595/Df; wnd1/wnd3 (n = 
13, 15, 10 and 9 cells, respectively). The DFsnf06595/Df mutant shows reduced EJP amplitude and reduced quantal content (p < 
0.001 for DFsnf06595/Df versus WT). These electrophysiological defects in the DFsnf06595/Df mutant are all rescued by presynap-
tic expression of DFsn (p < 0.001 for DFsnf06595/Df-Res versus DFsnf06595/Df;p > 0.5 for DFsnf06595/Df-Res versus WT). wallenda 
suppresses the reduction of mini frequency in the DFsnf06595/Df mutant (p > 0.5 for DFsnf06595/Df; wnd1/wnd3 versus WT). The 
EJP amplitude and the quantal content of the double mutant DFsnf06595/Df; wnd1/wnd3 are not significantly different than 
DFsnf06595/Df (p > 0.1), demonstrating that wallenda does not suppress the DFsnf06595/Df defect in evoked release.
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(G2054R) [3]. While hiwND51 and DFsnf06595 mutants each
show mild synaptic terminal overgrowth compared to
wild type, the double mutant shows dramatically over-
grown synapses (Figure 5). In addition to the large
increase in bouton number (Figure 5b), there is also
enhancement of synaptic branching, with the number of
branch points being: wild type, 2.2 ± 0.3 (n = 27);
hiwND51, 4.3 ± 0.3 (n = 27); DFsnf06595, 6.5 ± 0.4 (n = 34);
hiwND51, DFsnf06595, 10.8 ± 0.6 (n = 28). The enhancement
of a weak hiw allele by the DFsn hypomorph is consistent
with the two proteins acting in a complex; however, it is
also consistent with the two proteins acting in parallel
pathways. To distinguish between these possibilities, we
generated double mutants between the DFsnf06595 mutant
and hiwND9, a genetic null for highwire harboring a prema-
ture stop. If DFsn and Highwire function together, then
loss of DFsn should not enhance a highwire null, since it is
already without function. However, if the proteins work
in parallel pathways, then the DFsn phenotype would be
additive and it should enhance either a hypomorphic or
null highwire  allele. We found that DFsnf06595 does not
enhance  hiwND9. Instead, hiwND9  and the hiwND9,
DFsnf06595 double mutant have a very similar synaptic ter-
minal overgrowth phenotype (Figure 5). The double
mutant also fails to enhance the number of synaptic
branch points, with the number of branch points being:
hiwND9, 9.6 ± 0.8 (n = 22); hiwND9, DFsnf06595, 7.4 ± 0.4 (n
= 39). Synaptic terminal growth is not saturated in a
strong highwire mutant [13], so the absence of enhance-
ment by the addition of a DFsn mutant is strong genetic
evidence that DFsn and Highwire collaborate to restrain
synaptic terminal growth.
DFsn down-regulates the levels of the Wallenda/DLK 
kinase to restrain synaptic terminal growth
How do Highwire and DFsn regulate synaptic terminal
growth? In both fly and worm, Highwire/RPM-1 down-
regulates the protein levels of the Wallenda/DLK kinase.
Increased levels of Wallenda/DLK over-activate down-
stream MAP kinase cascades and lead to altered synapse
development. Mutations in wallenda/DLK  suppress the
highwire/rpm-1  phenotypes. However, in worm, FSN-1
regulates the levels of the tyrosine kinase ALK and ALK
mutants suppress the fsn-1 phenotype, leading to the sug-
gestion that FSN-1 regulates synapse development by
down-regulating ALK [17]. If Highwire and DFsn collabo-
rate as part of a ubiquitin ligase complex, then we predict
they should both regulate the same target protein. We
have found that ALK is postsynaptic at the Drosophila NMJ
(AD, unpublished observation), so we have focused our
attention on Wallenda.
We first tested if DFsn, like Highwire, regulates the levels
of Wallenda in the nervous system. Wallenda protein is
undetectable in the nerve cord of wild-type larvae, but is
abundant in the synaptic neuropil of ventral nerve cords
from DFsn mutants (Figure 6a,b). This staining is due to
Wallenda protein since it is absent in DFsn, wnd double
mutant animals. Expression of a DFsn transgene rescues
the increase in Wallenda levels in the DFsn mutant (Figure
6a,b). Hence, DFsn, like Highwire, is required to down-
regulate the levels of the Wallenda/DLK kinase. While
Highwire and DFsn are each necessary to down-regulate
Wallenda/DLK, their simultaneous over-expression in
neurons is not sufficient to reduce the level of Wallenda
protein (data not shown), indicating that the Hiw-DFsn
ubiquitin ligase complex likely includes other compo-
nents.
Having demonstrated that DFsn regulates Wallenda lev-
els, we tested whether Wallenda is required for synaptic
terminal overgrowth in the DFsn mutant. As shown in Fig-
ure 6c–f, loss of wallenda suppresses the synaptic mor-
phology defects of the DFsn  mutant, restoring bouton
number, branching number, and synaptic span to near
wild-type levels. Therefore, Wallenda is necessary for syn-
aptic terminal overgrowth in both the DFsn and highwire
mutants. While wnd mutants suppress the morphological
defects of the DFsn mutant, they do not suppress the elec-
trophysiological phenotype. Quantal content is not signif-
icantly different between DFsn single mutants and DFsn,
wnd double mutants, while both show impaired release
compared to wild type (p < 0.001; Figure 4d). Therefore,
DFsn, like Highwire, must regulate at least two pathways.
In both mutants, the down-regulation of Wallenda is nec-
essary to restrain synaptic terminal growth, while a genet-
ically separable pathway is involved in promoting
synaptic release.
Discussion
Highwire and RPM-1 act as ubiquitin ligases to regulate
synaptic development. Liao et al. [17] have proposed that,
in C. elegans, RPM-1 participates in an atypical SCF ubiq-
uitin ligase complex with the F-box protein FSN-1. Con-
sistent with this hypothesis, RPM-1 binds to FSN-1 as well
as to Skp-1 and Cullin-1, core components of SCF com-
plexes. In addition, FSN-1 null mutants have very similar
phenotypes to rpm-1 mutants at GABAergic synapses, but
weaker phenotypes in DD motoneurons and sensory neu-
rons. The difference in phenotypes suggests that RPM-1
interacts with other F-box proteins in addition to FSN-1,
acts as a ubiquitin ligase without an F-box partner, or has
ubiquitin-independent functions. The target of the RPM-
1/FSN-1 complex in C. elegans is not clear. Biochemical
and genetic data indicate that the receptor tyrosine kinase
ALK is the functionally relevant target for FSN-1 [17],
while the MAPKKK DLK is the functionally relevant target
for RPM-1 [10]. Our data in Drosophila support the model
from worms that RPM-1 and FSN-1 form a functional
ubiquitin ligase complex, but simplify the model by dem-Neural Development 2007, 2:16 http://www.neuraldevelopment.com/content/2/1/16
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DFsn genetically interacts with Highwire to restrain synaptic terminal growth Figure 5
DFsn genetically interacts with Highwire to restrain synaptic terminal growth. (a) Representative confocal images of muscle 4 
synapses co-stained with DVGLUT (green) and FasII (red), in wild-type (WT), DFsnf06595, hiwND51, hiwND51; DFsnf06595, hiwND9 and 
hiwND9; DFsnf06595 third instar larvae. (b) Quantification of bouton number of muscle 4 synapses in WT, DFsnf06595, hiwND51, 
hiwND51; DFsnf06595, hiwND9 and hiwND9; DFsnf06595 third instar larvae (n = 27, 34, 27, 28, 22, and 39 cells, respectively). The 
number of boutons in the hiwND51; DFsnf06595 double mutant is increased compared to hiwND51 (p < 0.001). The number of bou-
tons in the hiwND9; DFsnf06595 double mutant is not significantly different from hiwND9 (p > 0.5), demonstrating a lack of enhance-
ment of the hiwND9 phenotype by DFsnf06595.
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DFsn down-regulates the levels of the Wallenda/DLK kinase to restrain synaptic terminal growth Figure 6
DFsn down-regulates the levels of the Wallenda/DLK kinase to restrain synaptic terminal growth. (a) Staining for endogenous 
Wallenda in central nervous system neuropil in ventral nerve cords of wild-type (WT), DFsnf06595/Df [P(f06595)/Df(2R)7872], 
DFsnf06595/Df-Res [presynaptic rescue: P(f06595)/Df(2R)7872; elav Gal4/UAS-GFP-DFsn] and DFsnf06595/Df; wnd1/wnd3 third-
instar larvae. Upper panels show Wallenda staining alone, and lower panels show co-staining of Wallenda (red) with the synap-
tic marker HRP (horseradish peroxidase) (blue). (b) Quantification of average Wallenda staining in the neuropil of third-instar 
larvae for the genotypes shown in (a). The Wallenda intensity was measured for each genotype and the background intensity 
measured for DFsnf06595/Df; wnd1/wnd3 was subtracted. Wallenda staining in the DFsnf06595/Df mutant was significantly higher 
than WT (p < 0.001). Presynaptic expression of a GFP-DFsn transgene rescues the increase of Wallenda level (p > 0.5 for 
DFsnf06595/Df-Res versus WT). (c) Representative confocal images of muscle 4 synapses co-stained with DVGLUT (green) and 
FasII (red), in WT, DFsnf06595/Df and DFsnf06595/Df; wnd3 third instar larvae. (d-f) Quantification is shown for bouton number (d) 
and synaptic branch point number (e) and synaptic span (f) for WT, DFsnf06595/Df and DFsnf06595/Df; wnd3 (n = 23, 23, and 22 
cells, respectively). The wallenda mutant fully suppresses the morphological defects in the DFsnf06595/Df mutant (p > 0.1 for 
DFsnf06595/Df; wnd3 versus WT in number of boutons and branch points; p < 0.001 for DFsnf06595/Df; wnd3  versus DFsnf06595/Df 
in synaptic span, number of boutons and branch points).
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onstrating that in Drosophila both components target the
same substrate.
We demonstrate that Highwire binds the Drosophila
homolog of FSN-1, DFsn. Therefore, the physical associa-
tion of Highwire/RPM-1 and DFsn/FSN-1 is evolutionar-
ily conserved. While eukaryotic genomes can encode
hundreds of F-box proteins like DFsn, in worms, flies,
mice, and humans there is only a single F-box protein that
also contains an SPRY domain, and each is more closely
related by sequence to each other than to other F-box pro-
teins. Since the binding of DFsn/FSN-1 to Highwire/RPM-
1 is conserved, we speculate that the mouse and human
homologs of DFsn, F-box protein 45 and hCG1734196,
will bind to and function with Phr [23] and PAM [9], the
mouse and human homologs of Highwire, respectively.
Indeed, expression analysis demonstrates that both the F-
box protein 45 and Phr are expressed in a very similar pat-
tern in the mouse brain [24].
Our results suggest that the interaction of Highwire with
DFsn is required for Highwire activity. Loss-of-function
mutants for highwire  and  DFsn  have qualitatively and
quantitatively similar phenotypes – both are required to
restrain synaptic terminal growth and promote synaptic
release. Both Highwire and DFsn are necessary to down-
regulate the levels of the MAPKKK Wallenda/DLK, and
wallenda  mutants suppress the morphological but not
physiological phenotypes of both highwire  and  DFsn.
Finally, genetic data support the model that Highwire and
DFsn function together during synaptic development –
DFsn mutants enhance the phenotype of a highwire hypo-
morph but not of a highwire null. All of these data are con-
sistent with the model that Highwire and DFsn act
together to form a functional ubiquitin ligase complex. In
our model, this ligase complex targets Wallenda/DLK to
restrain synaptic terminal growth, and an unknown sub-
strate to promote synaptic function. We speculate that the
targeting of the Wallenda/DLK MAPKKK by the Highwire/
DFsn complex will be conserved from worms to mam-
mals. While Highwire and DFsn collaborate for synaptic
development, the male sterility of DFsn but not highwire
mutants suggests that DFsn has Highwire-independent
functions in other developmental processes.
Conclusion
Here we demonstrate that the F-box protein DFsn binds to
the RING-domain ubiquitin ligase Highwire and can
localize to the Drosophila NMJ. DFsn is required to restrain
synaptic growth and promote synaptic transmission.
Genetic interactions between DFsn and highwire mutants
indicate that DFsn and highwire function in the same path-
way. Finally, DFsn, like Highwire, regulates the levels of
the Wallenda/DLK kinase, and wallenda is necessary for
both DFsn- and Highwire-dependent synaptic terminal
overgrowth. These results support the model that High-
wire and DFsn form a functional ubiquitin ligase complex
that down-regulates the MAPKKK Wallenda/DLK to
restrain synaptic terminal growth.
Methods
Tandem-affinity-purification procedure
Transgenic flies carrying the UAS-NTAP-HiwΔRING  or
UAS-TAP  transgene driven by BG380 Gal4 driver were
expanded. Fresh adult flies were deep frozen and then vor-
texed. Fly heads were then collected by passing the flies
through sieves that separate the heads from other body
parts. The purification procedure was performed at 4°C.
Fly heads were homogenized with homogenization buffer
(50 mM Tris-HCl pH 7.5, 125 mM NaCl, 5% Glycerol,
0.7% NP40, 1.5 mM MgCl2, 25 mM NaF, 1 mM EDTA, 0.2
mM DTT, 1 mM Na3VO4, 0.05 mM MG1115, 1 mM
PMSF, Protease inhibitor cocktail (Roche Applied Science,
Indianapolis, IN, USA). Two sequential centrifuge steps
(17,000 rpm for 20 minutes and 45,000 rpm for 40 min-
utes) were used to clean the homogenate before loading
the first column. The following purification steps were
performed according to the Séraphin lab TAP protocol
[25]. Final elutions from the second column were divided
into two portions. The first portion was loaded to a SDS-
PAGE gel (Criterion XT 4–12%) followed by Sypro Ruby
staining. Individual bands were then excised, digested
with trypsin, and subjected to LC-MS/MS. The second por-
tion was precipitated, digested with trypsin and then sub-
jected to LC-MS/MS. The searching program MASCOT
(Matrix Science Inc., Boston, MA, USA) was used to iden-
tify the protein species. As a control, the TAP-only com-
plex was analyzed by SDS-PAGE and no bands higher
than 15 kDa were detected by Sypro Ruby staining.
Fly stocks
Flies were maintained at 25°C on normal food. The fol-
lowing strains were used in this study: Canton S (wild
type), P-f06595 (Exelixis Collection at Harvard Medical
School), Df(2R)7872 (Bloomington Stock Centre), elav
Gal4 (neuron specific) [26], BG380 Gal4 (neuron spe-
cific) [27], D42 Gal4 (motor neuron specific) [28], ELAV-
GeneSwitch [29], hiwND51 and hiwND9 [3,12], two wallenda
alleles: wnd1 and wnd3 [15].
Transgenic constructs
Generation of TAP-tagged full-length highwire transgenes
UAS-NTAP-Hiw and UAS-NTAP-HiwΔRING was described
previously [11] using the TAP vector [20]. A UAS-TAP
transgene was also generated for control purposes. A full-
length cDNA clone (Clone ID: LD47425) for DFsn
(CG4643) was obtained from Research Genetics (Hunts-
ville, AL, USA). The entire coding region of DFsn was sub-
cloned into pUAST-EGFP or pUAST-HM vector [30] to
generate  UAS-GFP-DFsn  and  UAS-His-Myc-DFsn  trans-Neural Development 2007, 2:16 http://www.neuraldevelopment.com/content/2/1/16
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genes. Transformant lines were generated using standard
techniques.
Immunoprecipitations and western blots
For immunoprecipitations, about 100 larval brains for
each sample were collected by manual dissection. Larval
brains were then homogenized in 0.5 ml lysis buffer (Tris-
HCl 50 mM pH 7.4; NaCl 150 mM; EDTA 1 mM; NaF 2
mM; NP-40 0.2%; NaDOC (Na deoxycholate) 0.2% and
protease inhibitors). Clean lysate was then incubated with
the rabbit α-Highwire antibody [11] (HIW2b, 1:80), the
mouse α-Myc antibody (9E10, 1:100), or the rabbit α-
DVGLUT antibody [31] (1:80) for 2 hours. Protein A
beads (25 ul; Roche) were added to the lysate. After over-
night incubation, the beads were washed four times with
lysis buffer before elution. HIW2b (1:250) and the mouse
α-Myc antibody (1:1,000) were then used to probe the
endogenous Highwire and the neuronally expressed Myc-
DFsn (driven by BG380 Gal4), respectively, in the IP com-
plex on western blots.
Immunocytochemistry
Endogenous Wallenda was detected using the WndA1
antisera as described [15]. For all other antibodies, larvae
were fixed in Bouin's solution (a 1:5:15 ratio of acetic
acid/formalin/picric acid) for 8 minutes. The rabbit α-
DVGLUT antibody was described previously [31], and
used at 1:5,000 dilution. The α-fasciclin II (FasII; 1D4)
antibody developed by Corey Goodman (Renovis, San
Francisco, CA, USA) was obtained from the Developmen-
tal Studies Hybridoma Bank developed under the auspices
of the NICHD and maintained by The University of Iowa,
Department of Biological Sciences, Iowa City, IA, USA,
and used at 1:5. To examine the localization of GFP-DFsn,
GFP-DFsn was expressed in neuronal tissues by driving
the UAS-GFP-DFsn transgene with ELAV-GeneSwitch in
the presence of RU486. The mouse monoclonal α-GFP
antibody (3E6; Invitrogen, Carlsbad, CA, USA) was then
used at 1: 800 dilution to detect the GFP-DFsn protein.
Imaging and analysis
Larvae were imaged on a Nikon (Tokyo, Japan) C1 confo-
cal microscope. All images were acquired in third instar
wild-type, mutant, and rescued larvae that had been
simultaneously stained. The gain was chosen as the maxi-
mum gain that did not saturate the signal for each sample.
A complete Z-stack was acquired for each NMJ or ventral
nerve cord and rendered as a maximum projection. All
quantifications were done at muscle 4 in segments A2–A4.
The muscle sizes for all genotypes were similar. The
number of type I boutons and the number of branch
points of type I boutons were counted following α-
DVGLUT and α-Fas II staining. A synaptic branch was
defined as an arborization containing at least 2 type I bou-
tons. Synaptic span was calculated by dividing the length
of type I synapses by the length of muscle. The length of
synapses and muscle were measured by an ocular
micrometer (Nikon). Statistical analysis was performed
and graphs were generated in Origin 7.0 (Origin Lab,
Northampton, MA, USA). Each sample is compared to
other samples in the group using ANOVA, with n for each
condition described in the figure legends. All histograms
are shown as mean ± standard error of the mean.
Electrophysiology
Intracellular electrophysiological recordings were per-
formed as described previously [32]. Both spontaneous
mEJPs and evoked EJPs were recorded in HL-3 saline con-
taining 0.47 mM Ca2+ [33]. At least 70 consecutive events
were measured per cell using MiniAnal (Synaptosoft,
Decatur, GA, USA) and averaged to determine the mean
mEJP. Events with a slow rise time were rejected as arti-
facts from neighboring electrically coupled muscle cells.
Evoked EJPs were recorded by stimulating the cut end of
the segmental nerve with a 1 ms depolarizing pulse as
described by Broadie [34]. Quantal content was estimated
by dividing the mean EJP by the mean mEJP without cor-
recting for non-linear summation, which would only have
increased the observed differences.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CW participated in the design of the study and performed
all the experiments and analysis except for the electro-
physiology. RWD performed the electrophysiological
experiments. AD conceived the study, participated in its
design and, together with CW, drafted the final manu-
script, which was read and approved by all the authors.
Additional material
Additional file 1
Expression of a DFsn transgene in motoneurons rescues the morphological 
phenotype of DFsn mutants. (a) Representative confocal images of muscle 
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